Feb 27, 2025 07:18AM
Dec 11, 2024 07:15AM
Jul 18, 2024 08:06AM
Jul 18, 2024 08:00AM
May 15, 2024 04:05PM
Jul 25, 2023 04:01PM
Jun 9, 2023 04:01PM NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares
Jun 7, 2023 05:17AM
Jun 6, 2023 11:25PM
Jun 6, 2023 04:02PM
Jun 6, 2023 04:01PM
Jun 5, 2023 07:03AM
Jun 5, 2023 07:00AM
Jun 5, 2023 05:55AM NewAmsterdam Pharma (NAMS) Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe
Jun 3, 2023 12:15PM
May 31, 2023 08:00AM
May 23, 2023 08:00AM
May 8, 2023 08:00AM
Apr 24, 2023 08:00AM
Apr 24, 2023 08:00AM
Apr 3, 2023 08:09AM NewAmsterdam Pharma (NAMS) Appoints Janneke van der Kamp to its Board of Directors
Apr 3, 2023 08:00AM
Apr 3, 2023 08:00AM
Mar 31, 2023 08:00AM
Mar 31, 2023 08:00AM
Mar 1, 2023 08:00AM
Mar 1, 2023 08:00AM
Feb 9, 2023 08:00AM NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference
Feb 9, 2023 08:00AM
Feb 6, 2023 08:08AM
Feb 6, 2023 08:00AM
Feb 6, 2023 08:00AM
Jan 17, 2023 08:00AM
Jan 17, 2023 08:00AM
Jan 17, 2023 08:00AM NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy
Dec 19, 2022 04:02PM
Dec 19, 2022 04:01PM
Dec 19, 2022 04:01PM
Dec 9, 2022 04:01PM
Dec 9, 2022 04:01PM
Nov 23, 2022 08:03AM
Nov 23, 2022 08:00AM NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising Safety and Efficacy Clinical Data, as a Potential
Nov 23, 2022 08:00AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All